Custo do tratamento de câncer de mama HER-2 positivo no SUS

Abstract

50 were invested in chemotherapy and outpatient procedures (APAC), being that 67% was allocated to SIII (36%) and SIV (31%) treatments. From the direct cost of individual treatment, the SIV represented five times the cost of SI, three times that of SII and twice that of SIII. Conclusion: This study showed that HER-2 positive breast cancer treatments are available for all stages of the disease in SUS today. However, there is an opportunity to more effective treatments in the early stages (neo / adjuvant), where today the largest portion of the population (69%) is concentrated and where the lowest per capita expenditure is allocated. These results suggest the need for resource allocation optimization to the initial phase of the disease where the chance of cure is greater and the consequent reduction of the amount of palliative treatments in the long term.